Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions
CTKB Stock Forecast
Cytek Biosciences stock forecast is as follows: an average price target of $8.50 (represents a 31.58% upside from CTKB’s last price of $6.46) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CTKB Price Target
The average price target for Cytek Biosciences (CTKB) is $8.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 31.58% upside from CTKB's last price of $6.46.
CTKB Analyst Ratings
According to 4 Wall Street analysts, Cytek Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CTKB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cytek Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Dave Westenberg | Piper Sandler | $8.50 | $6.15 | 38.21% | 31.58% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $16.00 | $14.08 | 13.64% | 147.68% |
| May 15, 2022 | David Westenberg | Piper Sandler | $12.00 | $9.38 | 27.93% | 85.76% |
The latest Cytek Biosciences stock forecast, released on May 13, 2024 by Dave Westenberg from Piper Sandler, set a price target of $8.50, which represents a 38.21% increase from the stock price at the time of the forecast ($6.15), and a 31.58% increase from CTKB last price ($6.46).
Cytek Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.50 |
| Last Closing Price | $6.46 | $6.46 | $6.46 |
| Upside/Downside | -100.00% | -100.00% | 31.58% |
In the current month, the average price target of Cytek Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytek Biosciences's last price of $6.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2023 | Stephens | Positive | Initialise | |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 12, 2022 | Goldman Sachs | Buy | Buy | Hold |
Cytek Biosciences's last stock rating was published by Piper Sandler on May 13, 2024. The company gave CTKB a "Overweight" rating, the same as its previous rate.
Cytek Biosciences Financial Forecast
Cytek Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $58.60M | $48.00M | $49.69M | $37.09M | $48.34M | $40.48M | $40.16M | $35.06M | $38.89M | $34.38M | $30.41M |
| Avg Forecast | $76.17M | $61.82M | $57.72M | $54.51M | $67.81M | $56.87M | $53.23M | $48.70M | $61.49M | $50.70M | $49.53M | $43.59M | $56.58M | $55.48M | $45.71M | $47.15M | $50.22M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| High Forecast | $78.20M | $63.47M | $59.26M | $55.97M | $69.62M | $58.39M | $54.65M | $49.65M | $62.46M | $51.49M | $50.85M | $44.75M | $58.09M | $55.48M | $46.93M | $48.41M | $51.56M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| Low Forecast | $73.74M | $59.85M | $55.88M | $52.77M | $65.65M | $55.06M | $51.53M | $47.84M | $60.99M | $49.90M | $47.95M | $42.20M | $54.78M | $55.48M | $44.25M | $45.64M | $48.62M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.87% | 1.09% | 0.79% | 0.96% | 0.94% | 1.01% | 1.08% | 1.07% | 1.03% | 1.08% |
Cytek Biosciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $43.59M, with a low forecast of $42.20M, and a high forecast of $44.75M. CTKB's average Quarter revenue forecast represents a -25.62% decrease compared to the company's last Quarter revenue of $58.60M (Dec 23).
Cytek Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $-3.59M | $-9.13M | $-8.37M | $4.80M | $3.27M | $800.00K | $-1.24M | $936.00K | $2.71M | $3.90M |
| Avg Forecast | $90.38K | $73.36K | $68.48K | $64.68K | $80.47K | $67.48K | $63.16K | $57.78K | $72.96K | $60.15K | $58.77K | $51.72K | $67.14K | $65.83K | $54.24K | $55.94K | $59.59K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| High Forecast | $92.79K | $75.32K | $70.31K | $66.41K | $82.61K | $69.29K | $64.85K | $58.91K | $74.11K | $61.10K | $60.34K | $53.10K | $68.93K | $65.83K | $55.69K | $57.44K | $61.18K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Low Forecast | $87.49K | $71.02K | $66.30K | $62.62K | $77.90K | $65.33K | $61.15K | $56.77K | $72.37K | $59.21K | $56.89K | $50.07K | $65.00K | $65.83K | $52.51K | $54.16K | $57.69K | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 49.49% | -54.54% | -168.27% | -149.57% | 80.57% | 1.64% | 0.44% | -0.83% | 0.56% | 1.76% | 3.00% |
1 analysts predict CTKB's average Quarter EBITDA for Mar 24 to be $51.72K, with a high of $53.10K and a low of $50.07K. This is -98.44% lower than Cytek Biosciences's previous annual EBITDA (Dec 23) of $3.32M.
Cytek Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $6.30M | $-6.46M | $-4.39M | $-6.81M | $3.53M | $1.67M | $-702.00K | $-2.16M | $-1.17M | $1.42M | $2.67M |
| Avg Forecast | $13.23M | $6.52M | $4.08M | $2.84M | $14.55M | $6.42M | $6.34M | $3.35M | $14.95M | $1.53M | $-380.70K | $-3.32M | $3.98M | $2.92M | $1.59M | $2.99M | $5.64M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| High Forecast | $13.68M | $6.75M | $4.22M | $2.94M | $15.06M | $6.64M | $6.56M | $4.47M | $17.44M | $1.58M | $-364.91K | $-3.18M | $4.12M | $3.02M | $1.65M | $3.09M | $5.84M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Low Forecast | $12.68M | $6.25M | $3.91M | $2.72M | $13.95M | $6.15M | $6.08M | $2.23M | $9.97M | $1.47M | $-393.91K | $-3.43M | $2.66M | $2.80M | $1.53M | $2.86M | $5.41M | $1.64M | $1.64M | $-1.31M | $3.29M | $3.07M | $1.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.58% | -2.21% | -2.75% | -2.28% | 0.63% | 1.01% | -0.43% | 1.64% | -0.35% | 0.46% | 2.03% |
Cytek Biosciences's average Quarter net income forecast for Mar 24 is $-3.32M, with a range of $-3.43M to $-3.18M. CTKB's average Quarter net income forecast represents a -152.69% decrease compared to the company's last Quarter net income of $6.30M (Dec 23).
Cytek Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.90M | $22.43M | $25.15M | $23.23M | $19.54M | $16.85M | $17.02M | $14.51M | $15.24M | $12.30M | $9.74M |
| Avg Forecast | $27.42M | $22.26M | $20.78M | $19.63M | $24.42M | $20.48M | $19.17M | $17.53M | $22.14M | $18.25M | $17.83M | $15.69M | $20.37M | $19.97M | $16.46M | $16.98M | $18.08M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| High Forecast | $28.16M | $22.86M | $21.34M | $20.15M | $25.07M | $21.02M | $19.68M | $17.88M | $22.49M | $18.54M | $18.31M | $16.11M | $20.92M | $19.98M | $16.90M | $17.43M | $18.57M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Low Forecast | $26.55M | $21.55M | $20.12M | $19.00M | $23.64M | $19.83M | $18.55M | $17.23M | $21.96M | $17.97M | $17.26M | $15.19M | $19.72M | $19.97M | $15.93M | $16.43M | $17.51M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.12% | 1.53% | 1.37% | 1.08% | 1.08% | 1.19% | 1.24% | 1.16% | 1.02% | 0.96% |
Cytek Biosciences's average Quarter SG&A projection for Mar 24 is $15.69M, based on 1 Wall Street analysts, with a range of $15.19M to $16.11M. The forecast indicates a -28.34% fall compared to CTKB last annual SG&A of $21.90M (Dec 23).
Cytek Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $-0.05 | $-0.03 | $-0.05 | $0.03 | $0.01 | $-0.01 | $-0.02 | $-0.01 | - | $0.02 |
| Avg Forecast | $0.10 | $0.05 | $0.03 | $0.02 | $0.11 | $0.05 | $0.05 | $0.03 | $0.11 | $0.01 | $-0.00 | $-0.03 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| High Forecast | $0.10 | $0.05 | $0.03 | $0.02 | $0.11 | $0.05 | $0.05 | $0.03 | $0.13 | $0.01 | $-0.00 | $-0.02 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Low Forecast | $0.10 | $0.05 | $0.03 | $0.02 | $0.11 | $0.05 | $0.05 | $0.02 | $0.08 | $0.01 | $-0.00 | $-0.03 | $0.02 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.61% | -2.15% | -2.69% | -2.23% | 0.61% | 0.80% | -0.42% | 1.61% | -0.43% | 0.19% | 2.04% |
According to 1 Wall Street analysts, Cytek Biosciences's projected average Quarter EPS for Mar 24 is $-0.03, with a low estimate of $-0.03 and a high estimate of $-0.02. This represents a -151.87% decrease compared to CTKB previous annual EPS of $0.05 (Dec 23).
Cytek Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.64 | $8.50 | 418.29% | Buy |
| INGN | Inogen | $9.12 | $26.00 | 185.09% | Buy |
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| SGHT | Sight Sciences | $3.62 | $7.50 | 107.18% | Hold |
| RXST | RxSight | $38.04 | $70.14 | 84.38% | Buy |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| LIVN | LivaNova | $49.94 | $68.25 | 36.66% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| CTKB | Cytek Biosciences | $6.43 | $8.50 | 32.19% | Buy |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| SRDX | Surmodics | $39.96 | $39.50 | -1.15% | Buy |